Low-level Influenza Activity but Increasing RSV Activity in BC

During week 47 (November 20 to 26, 2016), influenza activity remained at low but above expected levels for this time of year. An increasing proportion of respiratory syncytial virus (RSV) detections was observed, notably at the BC Children’s and Women’s Health Centre Laboratory.

At the BCCDC Public Health Laboratory, entero/rhinoviruses continued to be the most commonly detected respiratory virus during this period, although an increasing number of specimens was positive for RSV, comparable to influenza. Influenza positivity dropped to below 10% in week 47.

No new influenza outbreaks were reported from long-term care facilities (LTCFs) this week. A total of 13 influenza outbreaks have been reported so far this season (since week 37), 12 with influenza A(H3N2) detected and one with influenza B detected.

Medical Services Plan (MSP) claims for influenza illness continued to decline in week 47 following a spike earlier this season but remained above expected seasonal levels.

Since our last bulletin, 2 new cases of enterovirus D68 (EV-D68) were detected, bringing the total number of cases detected in BC since August 2016 to 62 cases.
British Columbia

Sentinel Physicians
For the third consecutive week, the proportion of patients with influenza-like illness (ILI) among those presenting to sentinel sites was significantly higher than the 10-year historical average. In week 47, the rate was 0.34%. So far, 60% of sentinel sites have reported data for this week.

Percent of patient visits to sentinel physicians due to influenza-like illness (ILI) compared to historical average, British Columbia, 2016-17

* Data are subject to change as reporting becomes more complete.
† 10-year historical average for 2016-17 season based on 2004-05 to 2015-2016 seasons, excluding 2008-09 and 2009-10 due to atypical seasonality; CI=confidence interval.

BC Children’s Hospital Emergency Room
In week 47, the proportion of visits to BC Children's Hospital Emergency Room (ER) attributed to ILI remained steady around 12%, consistent with the 5-year historical average for this time of year.

Percent of patients presenting to BC Children's Hospital ER attributed to influenza-like illness (ILI), British Columbia, 2016-17

Source: BCCH Admitting, Discharge, Transfer database (ADT). Data includes records with a triage chief complaint of "flu" or "influenza" or "fever/cough."

* 5-year historical average for 2016-17 season based on 2011-12 to 2015-16 seasons; CI=confidence interval.
Medical Services Plan

In week 47, BC Medical Services Plan (MSP) general practitioner claims for influenza illness (II), as a proportion of all submitted MSP claims, continued to decline in all regions of the province following a spike near the end of October, but remained above the 10-year 75th percentile overall.

Service claims submitted to MSP for influenza illness (II)* as a proportion of all submitted general practitioner service claims, British Columbia, 2016-17

* Influenza illness is tracked as the percentage of all submitted MSP general practitioner claims with ICD-9 code 487 (influenza).

Data for the period August 1, 2009 to July 31, 2010 have been excluded from the 10-year median calculation due to atypical seasonality during the 2009/2010 H1N1 pandemic year. MSP week beginning August 1, 2016 corresponds to sentinel ILI week 31; data are current to November 30, 2016.

Data provided by Population Health Surveillance and Epidemiology, BC Ministry of Health Services.
Laboratory Reports

BCCDC Public Health Laboratory

During week 47, 286 patients were tested for respiratory viruses at the BCCDC Public Health Laboratory (PHL). Of these, 20 (7%) tested positive for influenza A [10 A(H3N2) and 10 with subtype pending]; none tested positive for influenza B. Overall influenza positivity continued to decline slightly and dropped to below 10% in week 47. Enteroviruses continued to be the most commonly detected respiratory virus during this period, although the number of respiratory syncytial virus (RSV) positive specimens increased for the second consecutive week and were comparable to the number of influenza detections in week 47.

Cumulatively since week 40 (starting October 2, 2016), 219 (11%) patients tested positive for influenza at the BCCDC PHL, including 211 (96%) with influenza A [200 A(H3N2) and 11 subtype pending] and 8 (4%) with influenza B. No patients have tested positive for influenza A(H1N1)pdm09 so far this season.

So far during the 2016-17 season, influenza A(H3N2) has been the dominant subtype among influenza detections. The majority of influenza detections have been in elderly adults ≥65 years old, consistent with early season outbreak reports from LTCFs and dominant circulation of A(H3N2) subtype viruses so far this season. However, a greater proportion of influenza A(H3N2) detections during the 2016-17 season are in non-elderly individuals <64 years old compared to the same period of the last early dominant A(H3N2) season in 2014-15 (48% vs. 36%, respectively).

Data are current to November 30, 2016.
Cumulative number (since week 40) of influenza detections by type/subtype and age group, 
BCCDC Public Health Laboratory, 2016-17

Data are current to November 30, 2016; figure includes cumulative influenza detections for specimens collected from weeks 40-47.

Age distribution of influenza A(H3N2) detections (cumulative since week 40), 
BCCDC Public Health Laboratory, 2016-17

Data are current to November 30, 2016; figure includes cumulative influenza detections for specimens collected from weeks 40-47.
For the third consecutive week, the number of RSV-positive tests increased dramatically at the BC Children’s and Women’s Health Centre Laboratory. Of the 88 tests conducted, 30 (34%) were positive for RSV in week 47. Two (2%) tests were positive for influenza A and one (1%) was positive for influenza B.

* Positive rates were calculated using aggregate data. The denominators for each rate represent the total number of tests; multiple tests may be performed for a single specimen and/or patient.
Influenza-like Illness (ILI) Outbreaks

There have been no new influenza outbreaks reported from long-term care facilities (LTCFs) since our last bulletin. One school ILI outbreak in IHA has been reported so far in week 48.

Cumulatively during the 2016-17 season (since week 37, starting September 11, 2016), a total of 13 influenza outbreaks have been reported, including 12 in LTCFs and one in an acute care setting. All but one of the outbreaks had influenza A(H3N2) detected; one outbreak with influenza B detected was additionally reported.

A total of 3 school ILI outbreaks have also been reported so far during the 2016-17 season but without etiologic agent identified.

Number of influenza-like illness (ILI) outbreaks reported, compared to current sentinel ILI rate and historical average sentinel ILI rate, British Columbia 2016-17

* School-based ILI outbreak defined as >10% absenteeism on any day, most likely due to ILI.
† Facility-based influenza outbreaks defined as 2 or more ILI cases within 7-day period, with at least one laboratory-confirmed case of influenza.
‡ 10-year historical average for 2016-17 season based on 2004-05 to 2015-16 seasons, excluding 2008-09 and 2009-10 due to atypical seasonality.
Emerging Respiratory Viruses

Enterovirus D68 (EV-D68), British Columbia
Since our last bulletin, 2 new cases of enterovirus D68 (EV-D68) were detected at the BCCDC Public Health Laboratory, bringing the total number of cases detected in BC since August 2016 to 62 cases.

Of the 62 laboratory-confirmed EV-D68 cases reported in BC to date since August 2016, 48 (77%) were detected in children <10 years old, and of those, half (24/48, 50%) have been detected in infants/toddlers <2 years old. Over 60% of cases are male. Almost three-quarters of cases with known information have been hospitalized and one infant/toddler presented with acute flaccid myelitis (AFM). Cases have been detected in all regions of the province. EV-D68 cases have also been reported in other parts of Canada, the US, and Europe in recent months, including one case in a young child ≤2 years old in Alberta with acute flaccid paralysis.

In 2014, BC along with other Canadian provinces and US states, experienced a nationwide outbreak of EV-D68, with several cases associated with severe respiratory illness notably in children with asthma. During the 2014 outbreak in BC, cases were initially detected in August, with subsequent increase through September and peak in October. A summary of the 2014 outbreak was published in Euro Surveillance, available from: www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21283.

Of note, despite systematic testing of over 700 respiratory specimens at the BCCDC Public Health Laboratory for EV-D68 during August and September 2015, no EV-D68 cases were detected in BC last fall, consistent with an expected 2-3 year periodicity.

Generally most EV-D68 cases present with mild respiratory illness; however, EV-D68 infection has been associated with neurologic illness characterized by acute flaccid paralysis in a small subset of cases. People with asthma and other lung conditions may be at higher risk of more serious respiratory complications.
**National**

**FluWatch (week 46, November 13 to 19, 2016)**

Influenza activity is approaching seasonal levels with many regions in Canada reporting increasing influenza activity. In week 46, the percentage of tests positive for influenza remained similar to the previous week with 4.5% of tests positive for influenza. Influenza A(H3N2) continues to be the most common subtype detected. In week 46, 1.0% of visits to sentinel healthcare professionals were due to influenza-like symptoms. Eight laboratory-confirmed influenza outbreaks were reported in week 46, an increase from the previous week with the majority in LTCFs. Twenty-six hospitalizations were reported from participating provinces and territories in week 46; the majority were due to influenza A. Details are available at: [healthycanadians.gc.ca/diseases-conditions-maladies-affections/disease-maladie/flu-grippe/surveillance/fluwatch-reports-rapports-surveillance-influenza-eng.php](http://healthycanadians.gc.ca/diseases-conditions-maladies-affections/disease-maladie/flu-grippe/surveillance/fluwatch-reports-rapports-surveillance-influenza-eng.php).

**National Microbiology Laboratory (NML): Strain Characterization**

From September 1 to November 30, 2016, the National Microbiology Laboratory (NML) received 105 influenza viruses [89 A(H3N2), 6 A(H1N1)pdm09 and 10 B] from Canadian laboratories for antigenic characterization.

**Influenza A(H3N2):** Of the 89 influenza A(H3N2) viruses, only 40 (45%) had sufficient haemagglutination titre for antigenic characterization by haemagglutination inhibition (HI) assay. Of the 40 viruses characterized by HI assay, all were considered antigenically similar to A/Hong Kong/4801/2014, the WHO-recommended A(H3N2) component for the 2016-17 northern hemisphere influenza vaccine. Of the 32 of 40 (80%) viruses antigenically characterized with available sequencing information, 27 (84%) belonged to genetic group 3C.2a and 5 (16%) belonged to genetic group 3C.3a. Genetic characterization was performed to infer antigenic properties on the remaining 49 viruses that did not grow to sufficient haemagglutination titre for HI assay. Of the 49 viruses genetically characterized, all were reported to belong to genetic group 3C.2a, which includes the A/Hong Kong/4801/2014 vaccine strain.

**Influenza A(H1N1)pdm09: The 6 A(H1N1)pdm09 viruses characterized were antigenically similar to A/California/7/2009, the WHO-recommended A(H1N1) component for the 2016-17 northern hemisphere influenza vaccine.**

**Influenza B: Of the 10 influenza B viruses characterized, 7 (70%) were antigenically similar to a B/Brisbane/60/2008(Victoria lineage)-like virus, the WHO-recommended influenza B component for the 2016-17 northern hemisphere trivalent influenza vaccine. The remaining 3 (30%) viruses were characterized as a B/Phuket/3073/2013(Yamagata lineage)-like virus, the WHO-recommended influenza B component for the 2016-17 northern hemisphere quadrivalent influenza vaccine containing two influenza B components.**

**National Microbiology Laboratory (NML): Antiviral Resistance**

From September 1 to November 30, 2016, the NML received influenza viruses from Canadian laboratories for drug susceptibility testing.

**Amantadine:** Of the 43 influenza A viruses [39 A(H3N2) and 4 A(H1N1)pdm09] tested against amantadine, all were resistant.

**Oseltamivir:** Of the 102 influenza viruses [88 A(H3N2), 5 A(H1N1)pdm09 and 9 B] tested against oseltamivir, all were sensitive.

**Zanamivir:** Of the 102 influenza viruses [88 A(H3N2), 5 A(H1N1)pdm09 and 9 B] tested against zanamivir, all were sensitive.
International

USA (week 46, November 13 to 19, 2016)
During week 46, influenza activity increased slightly, but remained low in the United States. The most frequently identified influenza virus subtype reported by public health laboratories during week 46 was influenza A(H3N2). Of the 235 A(H3N2) viruses genetically characterized by the US CDC since May 2016, 78% belonged to genetic group 3C.2a, including the newly emerging subgroup 3C.2a1, and 22% to group 3C.3a based on analysis of HA gene segments. The percentage of respiratory specimens testing positive for influenza in clinical laboratories increased slightly, but remained low. The proportion of deaths attributed to pneumonia and influenza (P&I) was below the system-specific epidemic threshold. No influenza-associated pediatric deaths were reported. The proportion of outpatient visits for ILI was 1.6%, which is below the national baseline of 2.2%. The geographic spread of influenza in Guam, Puerto Rico, and the U.S. Virgin Islands was reported as regional; 11 states reported local activity; the District of Columbia and 36 states reported sporadic activity; and three states reported no activity. One human infection with an influenza A(H1N2) variant (H1N2v) virus was reported in Iowa. Details are available at: www.cdc.gov/flu/weekly/.

WHO (November 28, 2016)
Influenza activity in the temperate zone of the northern hemisphere has not yet picked up and remained at inter-seasonal levels. Influenza activity in temperate southern hemisphere countries was back at inter-seasonal levels.

- In North America and Europe, influenza activity was still low with few influenza virus detections and ILI levels below seasonal thresholds. In the United States, RSV activity continued to be reported.
- In East Asia, an increased level of influenza activity was reported in Southern China. Influenza A(H3N2) remained the dominant virus circulating.
- In Western Asia, influenza detections remained low.
- In the Caribbean countries, influenza and other respiratory virus activity remained low. In Central America, there was a slight increase in influenza virus activity but RSV continued to circulate in several countries as the predominant respiratory virus.
- In tropical South America, respiratory virus activities remained low with exception of Colombia where RSV activity continued to be reported.
- In tropical countries of South Asia, influenza virus detections remained low.
- In South East Asia, influenza activity continued to be reported at low levels in Cambodia, Lao People’s Democratic Republic (PDR), Thailand and Vietnam with influenza A(H3N2) virus predominating. In African region, influenza detections increased in Ghana with B viruses dominating.
- In temperate South America, influenza and RSV activity continue to decrease throughout the sub-region.
- In Oceania, influenza virus activity was at inter-seasonal levels.
- From October 31 to November 13, 2016, the WHO GISRS laboratories tested more than 75,463 specimens, of which 3,603 were positive for influenza viruses: 3,248 (90%) were typed as influenza A and 355 (10%) as influenza B. Of the sub-typed influenza A viruses, 63 (3%) were influenza A(H1N1)pdm09 and 2482 (98%) were influenza A(H3N2). Of the characterized B viruses, 34 (37%) belonged to the B/Yamagata lineage and 58 (63%) to the B/Victoria lineage.

Details are available at: www.who.int/influenza/surveillance_monitoring/updates/en/.
WHO Recommendations for Influenza Vaccines

WHO Recommendations for 2016-17 Northern Hemisphere Influenza Vaccine

On February 25, 2016, the WHO announced recommended strain components for the 2016-17 northern hemisphere trivalent influenza vaccine (TIV):*

- an A/California/7/2009 (H1N1)pdm09-like virus;†
- an A/Hong Kong/4801/2014 (H3N2)-like virus;‡
- a B/Brisbane/60/2008 (Victoria-lineage)-like virus.§

It is recommended that quadrivalent influenza vaccines (QIV) containing two influenza B viruses contain the above three viruses and a B/Phuket/3073/2013 (Yamagata-lineage)-like virus.

These recommended components are the same as those recommended for the 2016 Southern Hemisphere vaccine.

* Recommended strains represent a change for two of the three components used for the 2015-16 northern hemisphere vaccines.
† Recommended strain has been retained as the A(H1N1) component since the 2009 pandemic and has been included in the northern hemisphere vaccine since 2010-11.
‡ Recommended strain for the A(H3N2) component represents a phylogenetic clade-level change from a clade 3C.3a virus to a clade 3C.2a virus.
§ Recommended strain for the influenza B component represents a lineage-level change from a B/Yamagata-lineage virus to a B/Victoria-lineage virus.


WHO Recommendations for 2017 Southern Hemisphere Influenza Vaccine

On September 29, 2016, the WHO announced the recommended strain components for the 2017 southern hemisphere trivalent influenza vaccine (TIV):*

- an A/Michigan/45/2015 (H1N1)pdm09-like virus;†
- an A/Hong Kong/4801/2014 (H3N2)-like virus;
- a B/Brisbane/60/2008 (Victoria-lineage)-like virus.

It is recommended that quadrivalent influenza vaccines (QIV) containing two influenza B viruses contain the above three viruses and a B/Phuket/3073/2013 (Yamagata-lineage)-like virus.

* These recommended strains represent a change for one of the three components used for the 2016 southern hemisphere TIV and 2016-17 northern hemisphere TIV.
† Recommended strain represents a change from an A/California/7/2009-like virus, which had been retained as the A(H1N1)pdm09 component since the 2009 pandemic, to an A/Michigan/45/2015-like virus belonging to the emerging phylogenetic subclade 6B.1.

For further details: www.who.int/influenza/vaccines/virus/recommendations/2017_south/en/.
Additional Information

Explanatory Note:
The surveillance period for the 2016-17 influenza season is defined starting in week 40. Weeks 36-39 of the 2015-16 season are shown on graphs for comparison purposes.

List of Acronyms:

ACF: Acute Care Facility  
AI: Avian influenza  
FHA: Fraser Health Authority  
HBoV: Human bocavirus  
HMPV: Human metapneumovirus  
HSDA: Health Service Delivery Area  
IHA: Interior Health Authority  
ILI: Influenza-Like Illness  
LTCF: Long-Term Care Facility  
MSP: BC Medical Services Plan  
NHA: Northern Health Authority  
NML: National Microbiological Laboratory  
A(H1N1)pdm09: Pandemic H1N1 influenza (2009)  
RSV: Respiratory syncytial virus  
VCHA: Vancouver Coastal Health Authority  
VIHA: Vancouver Island Health Authority  
WHO: World Health Organization

Current AMMI Canada Guidelines on the Use of Antiviral Drugs for Influenza:  
www.ammi.ca/?ID=122&Language=ENG

Web Sites:

BCCDC Emerging Respiratory Pathogen Updates:  
www.bccdc.ca/health-professionals/data-reports/emerging-respiratory-virus-updates

Influenza Web Sites

Canada – Influenza surveillance (FluWatch): healthycanadians.gc.ca/diseases-conditions-maladies-affections/disease-maladie/flu-grippe/surveillance/index-eng.php  
USA Weekly Surveillance Reports: www.cdc.gov/flu/weekly/  
Joint ECDC – WHO/Europe weekly influenza update (Flu News Europe): flunewseurope.org  
WHO – Weekly Epidemiological Record: www.who.int/wer/en/  
WHO Collaborating Centre for Reference and Research on Influenza (Australia): www.influenzacentre.org/  

Avian Influenza Web Sites

World Organization for Animal Health: www.oie.int/eng/en_index.htm

Contact Us:

Tel: (604) 707-2510  
Fax: (604) 707-2516  
Email: InfluenzaFieldEpi@bccdc.ca

Communicable Disease Prevention and Control Services (CDPACS)  
BC Centre for Disease Control  
655 West 12th Ave, Vancouver BC V5Z 4R4

Online: www.bccdc.ca/health-professionals/data-reports/influenza-surveillance-reports
**Influenza-Like Illness (ILI) Outbreak Summary Report Form**

*Please complete and email to ilioutbreak@bccdc.ca*

**Note:** This form is for provincial surveillance purposes. Please notify your local health unit per local guidelines/requirements.

**ILI:** Acute onset of respiratory illness with fever and cough and with one or more of the following: sore throat, arthralgia, myalgia, or prostration which could be due to influenza virus. In children under 5, gastrointestinal symptoms may also be present. In patients under 5 or 65 and older, fever may not be prominent.

**Schools and work site outbreak:** greater than 10% absenteeism on any day, most likely due to ILI.

**Residential institutions (facilities) outbreak:** two or more cases of ILI within a seven-day period.

### Reporting Information

<table>
<thead>
<tr>
<th>Health unit/medical health officer notified?</th>
<th>Yes ☐</th>
<th>No ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>Person Reporting: ______________________</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title: ______________________</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Phone: ___________________________</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email: ______________________</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health Authority: _________________________</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HSDA: ______________________</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Full Facility Name: _______________________</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Is this report:

- ☐ First Notification *(complete section B below; Section D if available)*
- ☐ Update *(complete section C below; Section D if available)*
- ☐ Outbreak Over *(complete section C below; Section D if available)*

### First Notification

**Type of facility:**

- ☐ LTCF
- ☐ Acute Care Hospital
- ☐ Senior’s Residence
  *(if ward or wing, please specify name/number: ______________________)*
- ☐ Workplace
- ☐ School *(grades: )*
- ☐ Other *(___________)*

**Date of onset of first case of ILI (dd/mm/yyyy):**

<table>
<thead>
<tr>
<th>Numbers to date</th>
<th>Residents/Students</th>
<th>Staff</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>With ILI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitalized</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Died</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Update AND Outbreak Declared Over

**Date of onset for most recent case of ILI (dd/mm/yyyy):**

If over, date outbreak declared over (dd/mm/yyyy):

<table>
<thead>
<tr>
<th>Numbers to date</th>
<th>Residents/Students</th>
<th>Staff</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>With ILI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitalized</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Died</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Laboratory Information

**Specimen(s) submitted?**

- ☐ Yes *(location: _______________)*
- ☐ No
- ☐ Don’t know

If yes, organism identified?

- ☐ Yes *(specify: _______________)*
- ☐ No
- ☐ Don’t know

---

Communicable Disease Prevention & Control Services  
655 W. 12th Ave.  
Vancouver BC V5Z 4R4  
Phone: (604) 707-2510  
Fax: (604) 707-2516  
ilioutbreak@bccdc.ca